Literature DB >> 28347252

The critical role and potential target of the autotaxin/lysophosphatidate axis in pancreatic cancer.

Ming Quan1, Jiu-Jie Cui1, Xiao Feng1, Qian Huang1.   

Abstract

Autotaxin, an ecto-lysophospholipase D encoded by the human ENNP2 gene, is expressed in multiple tissues, and participates in numerous critical physiologic and pathologic processes including inflammation, pain, obesity, embryo development, and cancer via the generation of the bioactive lipid lysophosphatidate. Overwhelming evidences indicate that the autotaxin/lysophosphatidate signaling axis serves key roles in the numerous processes central to tumorigenesis and progression, including proliferation, survival, migration, invasion, metastasis, cancer stem cell, tumor microenvironment, and treatment resistance by interacting with a series of at least six G-protein-coupled receptors (LPAR1-6). This review provides an overview of the autotaxin/lysophosphatidate axis and collates current knowledge regarding its specific role in pancreatic cancer. With a deeper understanding of the critical role of the autotaxin/lysophosphatidate axis in pancreatic cancer, targeting autotaxin or lysophosphatidate receptor may be a potential and promising strategy for cancer therapy.

Entities:  

Keywords:  Autotaxin/ENPP2; cancer pathophysiology; cancer therapy; lysophosphatidate; lysophosphatidate receptor; pancreatic cancer

Mesh:

Substances:

Year:  2017        PMID: 28347252     DOI: 10.1177/1010428317694544

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  9 in total

1.  Clinical Usefulness of Serum Autotaxin for Early Prediction of Relapse in Male Patients with Type 1 Autoimmune Pancreatitis.

Authors:  Ayami Fukiage; Hatsue Fujino; Daiki Miki; Yasutaka Ishii; Masahiro Serikawa; Masataka Tsuge; Michio Imamura; Hiroshi Aikata; C Nelson Hayes; Kazuaki Chayama
Journal:  Dig Dis Sci       Date:  2020-05-20       Impact factor: 3.199

2.  Discovery of bladder cancer biomarkers in paired pre- and postoperative urine samples.

Authors:  Xuechao Li; Chuanxi Huang; Xueli Zhang; Tao Yang; Shidong Zuo; Chengwei Fu; Yongjie Zhang; Chunyuan Yang; Lijun Chen
Journal:  Transl Androl Urol       Date:  2021-08

3.  Development and validation of a ferroptosis-related prognostic model in pancreatic cancer.

Authors:  Chen-Jie Qiu; Xue-Bing Wang; Zi-Ruo Zheng; Chao-Zhi Yang; Kai Lin; Kai Zhang; Min Tu; Kui-Rong Jiang; Wen-Tao Gao
Journal:  Invest New Drugs       Date:  2021-06-30       Impact factor: 3.850

4.  Evaluation of serum ATX and LPA as potential diagnostic biomarkers in patients with pancreatic cancer.

Authors:  Jiang Chen; Hongyu Li; Wenda Xu; Xiaozhong Guo
Journal:  BMC Gastroenterol       Date:  2021-02-10       Impact factor: 3.067

5.  Association between the Expression Levels of MicroRNA-101, -103, and -29a with Autotaxin and Lysophosphatidic Acid Receptor 2 Expression in Gastric Cancer Patients.

Authors:  Sara Tutunchi; Saeedeh Akhavan; Ghodratollah Panahi; Mina Zare; Amirnader Emami Razavi; Reza Shirkoohi
Journal:  J Oncol       Date:  2022-04-11       Impact factor: 4.501

Review 6.  KAI1/CD82 gene and autotaxin-lysophosphatidic acid axis in gastrointestinal cancers.

Authors:  Shuo Wang; Jiang Chen; Xiao-Zhong Guo
Journal:  World J Gastrointest Oncol       Date:  2022-08-15

7.  Tumours modulate the systemic vascular response to anti-angiogenic therapy.

Authors:  Adam Hargreaves; Simon T Barry; Alison Bigley; Jane Kendrew; Shirley Price
Journal:  J Appl Toxicol       Date:  2022-03-02       Impact factor: 3.628

Review 8.  The LPA3 Receptor: Regulation and Activation of Signaling Pathways.

Authors:  Karina Helivier Solís; M Teresa Romero-Ávila; Alejandro Guzmán-Silva; J Adolfo García-Sáinz
Journal:  Int J Mol Sci       Date:  2021-06-23       Impact factor: 5.923

Review 9.  Coming of Age for Autotaxin and Lysophosphatidate Signaling: Clinical Applications for Preventing, Detecting and Targeting Tumor-Promoting Inflammation.

Authors:  Matthew G K Benesch; Iain T K MacIntyre; Todd P W McMullen; David N Brindley
Journal:  Cancers (Basel)       Date:  2018-03-15       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.